OPT 302

Drug Profile

OPT 302

Alternative Names: OPT-302; VGX 300

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator Vegenics
  • Developer Opthea
  • Class Eye disorder therapies
  • Mechanism of Action Vascular endothelial growth factor C inhibitors; Vascular endothelial growth factor D inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration

Most Recent Events

  • 20 Mar 2017 Opthea plans a phase IIb trial for Wet age-related macular degeneration (Treatment-naive) in USA, United Kingdom and European Union (Intravitreous, Injection)
  • 25 Jul 2016 Interim efficacy data from a phase I/II trial in Wet age-related macular degeneration released by Opthea
  • 25 Jul 2016 Opthea plans a phase IIb trial for wet age-related macular degeneration in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top